Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling
- PMID: 17295608
- DOI: 10.1359/jbmr.070211
Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling
Abstract
We found a novel heterozygous missense mutation (M282V) in the LRP5 gene in a patient with a high bone mass phenotype. In vitro studies suggest that a reduced antagonistic effect of DKK1 on canonical Wnt signaling contributes to the molecular effect of this mutation and its pathogenic consequence.
Introduction: Gain-of-function mutations in the gene encoding LDL receptor-related protein 5 (LRP5) cause high bone mass. Recent studies revealed that a reduced inhibition of canonical Wnt signaling by Dickkopf 1 (DKK1) contributes to the pathophysiology of this disease phenotype.
Materials and methods: We report on a 55-yr-old female patient with a high bone mass phenotype. Sequencing of exons 2-4 of the LRP5 gene was carried out to screen for disease-associated mutations in genomic DNA of the patient. The effect of the identified mutation on LRP5 membrane trafficking was studied by immunoblotting of a truncated form of LRP5. Additionally, Wnt signal activation in the absence and presence of DKK1 was assessed using a TCF4-based reporter gene assay in Saos-2 cells.
Results: Our patient presents with dense bones (Z-scores > +6), and radiographic examination showed a generalized thickening of the skeleton. BMD at the hip and lumbar spine significantly decreased through the passage to menopause, indicating no protection to bone loss. Further clinical evaluation revealed torus palatinus. Mutation analysis showed the presence of a novel heterozygous missense variant (844A-->G; M282V) in LRP5, located in the first beta-propeller domain of the extracellular portion. Although protein secretion seemed to be impaired, this mutant was able to transduce Wnt signals at levels comparable with wildtype LRP5. We additionally observed a less efficient inhibition of canonical Wnt signaling by DKK1.
Conclusions: Like all high BMD-associated gain-of-function LRP5 mutations described thus far, the M282V variant affects an amino acid located in the first beta-propeller domain, underlining the functional importance of this region in the pathophysiology of these conditions. This mutation most likely alters a region important for LRP5 modulation by DKK.
Similar articles
-
Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation.J Bone Miner Res. 2005 May;20(5):878-85. doi: 10.1359/JBMR.041223. Epub 2004 Dec 20. J Bone Miner Res. 2005. PMID: 15824861
-
Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.Gene. 2007 Apr 15;391(1-2):103-12. doi: 10.1016/j.gene.2006.12.014. Epub 2006 Dec 29. Gene. 2007. PMID: 17276019
-
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.Mol Cell Biol. 2005 Jun;25(12):4946-55. doi: 10.1128/MCB.25.12.4946-4955.2005. Mol Cell Biol. 2005. PMID: 15923613 Free PMC article.
-
LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.Joint Bone Spine. 2005 May;72(3):207-14. doi: 10.1016/j.jbspin.2004.10.008. Joint Bone Spine. 2005. PMID: 15850991 Review.
-
Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.Curr Opin Lipidol. 2005 Apr;16(2):207-14. doi: 10.1097/01.mol.0000162326.62419.e4. Curr Opin Lipidol. 2005. PMID: 15767861 Review.
Cited by
-
Wnt pathway in bone: knowledge structure and hot spots from 1993 to 2022.Front Physiol. 2023 Nov 16;14:1279423. doi: 10.3389/fphys.2023.1279423. eCollection 2023. Front Physiol. 2023. PMID: 38033331 Free PMC article.
-
A Case of Endosteal Hyperostosis Caused by a Mutation of the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene.Cureus. 2025 May 30;17(5):e85100. doi: 10.7759/cureus.85100. eCollection 2025 May. Cureus. 2025. PMID: 40585686 Free PMC article.
-
Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.J Biol Chem. 2010 Dec 31;285(53):41614-26. doi: 10.1074/jbc.M110.153890. Epub 2010 Oct 15. J Biol Chem. 2010. PMID: 20952383 Free PMC article.
-
Genetic variants in the LRP5 gene associated with gain and loss of bone mineral density.In Silico Pharmacol. 2025 Apr 16;13(2):61. doi: 10.1007/s40203-025-00341-5. eCollection 2025. In Silico Pharmacol. 2025. PMID: 40255261
-
LRP receptor family member associated bone disease.Rev Endocr Metab Disord. 2015 Jun;16(2):141-8. doi: 10.1007/s11154-015-9315-2. Rev Endocr Metab Disord. 2015. PMID: 26048454 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases